Andrea Treyer (A Treyer)

Publication Activity (10 Years)

Years Active: 2015-2021
Publications (10 Years): 5

Top Topics

Cardiovascular Risk Factors

Top Venues

The pharmacogenomics journal

RSC medicinal chemistry

Molecular pharmaceutics

Journal of medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Chiara Borsari, Erhan Keles, Andrea Treyer, Martina De Pascale, Paul Hebeisen, Matthias Hamburger, Matthias P Wymann
Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability. RSC medicinal chemistry 12 (4) (2021)
Chiara Borsari, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker, Lukas Bissegger, Martina De Pascale, Anna Melone, Rohitha Sriramaratnam, Florent Beaufils, Matthias Hamburger, Paul Hebeisen, Wolfgang Löscher, Doriano Fabbro, Petra Hillmann, Matthias P Wymann
4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. Journal of medicinal chemistry 63 (22) (2020)
Andrea Treyer, Sandra Walday, Hinnerk Boriss, Pär Matsson, Per Artursson
A Cell-Free Approach Based on Phospholipid Characterization for Determination of the Cell Specific Unbound Drug Fraction (fu,cell). Pharmaceutical research 36 (12) (2019)
Andrea Treyer, Mohammed Ullah, Neil Parrott, Birgit Molitor, Stephen Fowler, Per Artursson
Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies. The AAPS journal 21 (5) (2019)
Andrea Treyer, André Mateus, Jacek R Wiśniewski, Hinnerk Boriss, Pär Matsson, Per Artursson
Intracellular Drug Bioavailability: Effect of Neutral Lipids and Phospholipids. Molecular pharmaceutics 15 (6) (2018)
L Quteineh, P-Y Bochud, D Golshayan, S Crettol, J-P Venetz, O Manuel, Zoltán Kutalik, Andrea Treyer, R Lehmann, N J Mueller, I Binet, C van Delden, J Steiger, P Mohacsi, J-F Dufour, P M Soccal, M Pascual, C B Eap, null null
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. The pharmacogenomics journal 17 (1) (2015)